Which has better earnings and valuation, ARGX or ROIV?

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.67 $1.29B $22.46 38.31 Roivant Sciences $8.26M 3,005.09 -$299.77M -$0.60 N/A

Is ARGX or ROIV more profitable?

argenex has a net margin of 31.31% compared to Roivant Sciences' net margin of -3,629.19%. argenex's return on equity of 44.37% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% Roivant Sciences -3,629.19% -20.54% -19.43%

Does the media refer more to ARGX or ROIV?

In the previous week, argenex had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for argenex and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.09 beat argenex's score of 0.93 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ROIV or TAK?

Roivant Sciences presently has a consensus target price of $33.59, suggesting a potential downside of 2.66%. Given Roivant Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Roivant Sciences is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer ROIV or TAK?

In the previous week, Roivant Sciences had 3 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for Takeda Pharmaceutical. Roivant Sciences' average media sentiment score of 1.09 beat Takeda Pharmaceutical's score of 0.65 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or RVMD?

In the previous week, Roivant Sciences had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 9 mentions for Roivant Sciences and 4 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.73 beat Roivant Sciences' score of 1.09 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor TEVA or ROIV?

In the previous week, Teva Pharmaceutical Industries had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 9 mentions for Roivant Sciences. Teva Pharmaceutical Industries' average media sentiment score of 1.37 beat Roivant Sciences' score of 1.09 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 12 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or ONC?

In the previous week, BeOne Medicines had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for BeOne Medicines and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.09 beat BeOne Medicines' score of 0.33 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Roivant Sciences (ROIV) Competitors

$34.51 0.00 (0.00%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$35.15 +0.64 (+1.85%)

As of 04:30 AM Eastern

Compare

ROIV vs. ARGX, TAK, RVMD, TEVA, and ONC

Should you buy Roivant Sciences stock or one of its competitors? MarketBeat compares Roivant Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Roivant Sciences include argenex (ARGX), Takeda Pharmaceutical (TAK), Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does Roivant Sciences compare to argenex?

argenex (NASDAQ:ARGX) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

60.3% of argenex shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

argenex has a net margin of 31.31% compared to Roivant Sciences' net margin of -3,629.19%. argenex's return on equity of 44.37% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

argenex has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

argenex currently has a consensus price target of $1,037.61, indicating a potential upside of 20.58%. Roivant Sciences has a consensus price target of $33.59, indicating a potential downside of 2.66%. Given argenex's stronger consensus rating and higher possible upside, research analysts plainly believe argenex is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.67	$1.29B	$22.46	38.31
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A

In the previous week, argenex had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for argenex and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.09 beat argenex's score of 0.93 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats Roivant Sciences on 12 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Takeda Pharmaceutical?

Roivant Sciences (NASDAQ:ROIV) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Roivant Sciences has higher earnings, but lower revenue than Takeda Pharmaceutical. Roivant Sciences is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A
Takeda Pharmaceutical	$28.32B	1.94	-$1.01B	$0.39	43.98

Roivant Sciences presently has a consensus target price of $33.59, suggesting a potential downside of 2.66%. Given Roivant Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Roivant Sciences is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Takeda Pharmaceutical has a net margin of 4.31% compared to Roivant Sciences' net margin of -3,629.19%. Takeda Pharmaceutical's return on equity of 11.20% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

Roivant Sciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

In the previous week, Roivant Sciences had 3 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for Takeda Pharmaceutical. Roivant Sciences' average media sentiment score of 1.09 beat Takeda Pharmaceutical's score of 0.65 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Roivant Sciences beats Takeda Pharmaceutical on 10 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to Revolution Medicines?

Roivant Sciences (NASDAQ:ROIV) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Roivant Sciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, Roivant Sciences had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 9 mentions for Roivant Sciences and 4 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.73 beat Roivant Sciences' score of 1.09 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Roivant Sciences currently has a consensus price target of $33.59, suggesting a potential downside of 2.66%. Revolution Medicines has a consensus price target of $144.00, suggesting a potential downside of 22.65%. Given Roivant Sciences' higher possible upside, equities analysts plainly believe Roivant Sciences is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Roivant Sciences has higher earnings, but lower revenue than Revolution Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A
Revolution Medicines	$11.58M	3,417.76	-$1.13B	-$7.07	N/A

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Revolution Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Revolution Medicines	N/A	-83.22%	-59.06%

Summary

Revolution Medicines beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

In the previous week, Teva Pharmaceutical Industries had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 9 mentions for Roivant Sciences. Teva Pharmaceutical Industries' average media sentiment score of 1.37 beat Roivant Sciences' score of 1.09 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	12 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.13	$1.41B	$1.33	24.06
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Teva Pharmaceutical Industries presently has a consensus target price of $41.78, indicating a potential upside of 30.57%. Roivant Sciences has a consensus target price of $33.59, indicating a potential downside of 2.66%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Roivant Sciences' net margin of -3,629.19%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats Roivant Sciences on 11 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to BeOne Medicines?

Roivant Sciences (NASDAQ:ROIV) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Roivant Sciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to Roivant Sciences' net margin of -3,629.19%. BeOne Medicines' return on equity of 12.06% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
BeOne Medicines	8.94%	12.06%	6.69%

BeOne Medicines has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A
BeOne Medicines	$5.34B	6.41	$286.93M	$4.47	69.80

Roivant Sciences currently has a consensus target price of $33.59, indicating a potential downside of 2.66%. BeOne Medicines has a consensus target price of $390.92, indicating a potential upside of 25.29%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, BeOne Medicines had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for BeOne Medicines and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.09 beat BeOne Medicines' score of 0.33 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BeOne Medicines beats Roivant Sciences on 12 of the 17 factors compared between the two stocks.

Get Roivant Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ROIV vs. The Competition

Export

Metric	Roivant Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.82B	$3.69B	$6.86B	$12.27B
Dividend Yield	N/A	2.17%	2.67%	9.36%
P/E Ratio	-57.52	21.21	27.23	23.92
Price / Sales	3,005.09	304.52	581.44	113.62
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	4.70	8.28	10.62	6.18
Net Income	-$299.77M	$23.81M	$3.59B	$331.89M
7 Day Performance	N/A	-1.34%	-1.06%	-1.28%
1 Month Performance	9.80%	2.68%	1.63%	-1.36%
1 Year Performance	201.66%	45.93%	25.61%	17.73%

Roivant Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ROIV Roivant Sciences	1.8337 of 5 stars	$34.51 flat	$33.59 -2.7%	+201.7%	$24.82B	$8.26M	N/A	860
ARGX argenex	4.6351 of 5 stars	$876.25 -0.2%	$1,037.61 +18.4%	+52.4%	$54.58B	$4.25B	39.01	1,863	Upcoming Earnings
TAK Takeda Pharmaceutical	1.9341 of 5 stars	$16.49 -0.4%	N/A	+18.9%	$52.70B	$28.32B	42.28	47,000	Analyst Upgrade
RVMD Revolution Medicines	1.9897 of 5 stars	$183.95 -1.6%	$144.00 -21.7%	+386.1%	$39.73B	$11.58M	N/A	250	Gap Down
TEVA Teva Pharmaceutical Industries	4.8084 of 5 stars	$32.15 -2.4%	$41.78 +29.9%	+99.0%	$37.89B	$17.26B	24.17	33,950	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ROIV) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roivant Sciences (ROIV) Competitors

ROIV vs. ARGX, TAK, RVMD, TEVA, and ONC

How does Roivant Sciences compare to argenex?

Summary

How does Roivant Sciences compare to Takeda Pharmaceutical?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Summary

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Summary

How does Roivant Sciences compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roivant Sciences (ROIV) Competitors

ROIV vs. ARGX, TAK, RVMD, TEVA, and ONC

How does Roivant Sciences compare to argenex?

Do institutionals & insiders have more ownership in ARGX or ROIV?

Is ARGX or ROIV more profitable?

Which has more risk & volatility, ARGX or ROIV?

Do analysts recommend ARGX or ROIV?

Which has better earnings and valuation, ARGX or ROIV?

Does the media refer more to ARGX or ROIV?

Summary

How does Roivant Sciences compare to Takeda Pharmaceutical?

Do insiders & institutionals hold more shares of ROIV or TAK?

Which has preferable earnings and valuation, ROIV or TAK?

Do analysts prefer ROIV or TAK?

Is ROIV or TAK more profitable?

Which has more risk & volatility, ROIV or TAK?

Does the media prefer ROIV or TAK?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Which has more volatility & risk, ROIV or RVMD?

Does the media prefer ROIV or RVMD?

Do analysts rate ROIV or RVMD?

Which has stronger valuation and earnings, ROIV or RVMD?

Do insiders and institutionals hold more shares of ROIV or RVMD?

Is ROIV or RVMD more profitable?

Summary

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Does the media favor TEVA or ROIV?

Which has stronger earnings and valuation, TEVA or ROIV?

Which has more risk and volatility, TEVA or ROIV?

Do analysts recommend TEVA or ROIV?

Is TEVA or ROIV more profitable?

Do institutionals and insiders have more ownership in TEVA or ROIV?

Summary

How does Roivant Sciences compare to BeOne Medicines?

Do institutionals and insiders believe in ROIV or ONC?

Which has more volatility & risk, ROIV or ONC?

Is ROIV or ONC more profitable?

Which has stronger earnings & valuation, ROIV or ONC?

Do analysts prefer ROIV or ONC?

Does the media prefer ROIV or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools